News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting -
